(ALIGN) - A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function

Project: Research

Project Details

StatusActive
Effective start/end date7/05/216/05/26

Keywords

  • clinical trial
  • treatment safety
  • treatment efficacy
  • renal function
  • phase 3 study